Global Bladder Cancer Treatment Market Report and Forecast 2024-2032

Global Bladder Cancer Treatment Market Outlook

The bladder cancer treatment market size was close to USD 4.03 billion in 2023, driven by the rising number of bladder cancer cases. The bladder cancer treatment market is likely to grow at a CAGR of 9.31% during the forecast period of 2024-2032 to reach a value of USD 8.98 billion by 2032, driven by the rise in unhealthy lifestyles.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Bladder Cancer Insights

Bladder cancer develops in the tissues of the urinary tract and is known as urological cancer. Cell division occurs uncontrollably in the epithelium and can spread into the bladder's muscular wall.

There is still no clear understanding of what causes bladder cancer. Depending on the type of cancerous cells, bladder cancer can be divided into three categories. The following types are: 

Transitional Cell Carcinoma: This type of cancer is also called urothelial carcinoma. The disease occurs in bladder lining cells called urothelial cells. Among all bladder cancer types, this is the most common one.

Squamous Cell Carcinoma: A prolonged infection or stimulation leads to the development of this type of cancer in the bladder.

Adenocarcinoma: Bladder cancer occurs in glands located in the bladder lining. There are only a few cases of this type of bladder cancer.

There are several ways in which non-muscle invasive bladder cancer can be detected, including blood tests, urine cytology, cystoscopy, and computerised tomography. 

Chemotherapy, immunotherapy, or surgery are the preferred treatment methods for bladder cancer. 

On the other hand, prolonged exposure to radiation, tobacco consumption, chronic bladder infections, and smoking are among the risk factors. Any age group is susceptible to this condition. The condition is more common in older adults. Additionally, smoking is the leading cause of bladder cancer in the world.

According to the market research report, the bladder cancer treatment market can be categorised into the following segments: 

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Type

• Invasive Bladder Cancer
  • Non-Muscle-Invasive Bladder Cancer
  • Muscle-Invasive Bladder Cancer
• Transitional Bladder Cancer

• Squamous Cell Bladder Cancer

• Others

Market Breakup by Diagnosis Method

• Cystoscopy

• Biopsy

• Urine Cytology

• Imaging Tests

Market Breakup by Treatment Method

• Surgery

• Intravesical Chemotherapy

• Systemic Chemotherapy

• Radiation Therapy

• Immunotherapy

• Targeted Therapy

Market Breakup by Treatment Channel

• Public

• Private

Market Breakup by Region

• North America
  • United States of America
  • Canada
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
• Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Scenario

The bladder cancer treatment market growth is expected to be influenced by unhealthy lifestyles, such as bladder infections, genetic abnormalities, smoking, and chemical exposure. The bladder cancer treatment market is further expected to grow due to improvements in cancer treatment methods.

The market growth is predicted to be driven by an aging population as well. Increased treatment costs will further limit the growth of the market over the long term. Moreover, emerging markets offer opportunities for market growth. The bladder cancer therapy market, however, may be further hampered by post-treatment side effects.

North America Dominates the Global Bladder Cancer Treatment Market

The market in North America is largely driven by technological advances in medicine, especially cancer treatment. Moreover, bladder cancer treatment will benefit from increased healthcare spending in this region. 

Research and development are expected to drive the bladder cancer treatment market growth in Asia-Pacific. 

The availability of generic drugs and government awareness programs are also expected to generate significant growth in this region over the next few years.

Therapeutic Landscape

Currently, researchers are testing immune checkpoint inhibitors for bladder cancer in the early stages and in combination with other treatments. The research includes: 

• A drug called nivolumab (Opdivo) has been approved by the United States Food and Drug Administration in 2021, as an additional (adjuvant) treatment for patients with urothelial cancer who are at high risk of recurrence after surgery. It was the first FDA approval for this type of adjuvant treatment.

• Avelumab (Bavencio), an immune checkpoint inhibitor, was approved by the FDA in 2020 for patients with advanced bladder cancer which has shrunk or stopped growing after receiving platinum-based chemotherapy. 

Avelumab has been approved for the adjuvant treatment of bladder cancer that has not metastasized (locally advanced) or that has spread beyond the bladder (metastatic carcinoma).

Clinical Trial

Bladder cancer treatment depends on the type and stage of the disease. Research on new treatments and drugs is ongoing in addition to new combinations of existing treatments. 

Drugs used in targeted therapy target specific cancer cells while causing little damage to normal cells. FDA approved erdafitinib (Balversa) for patients with locally advanced or metastatic urothelial cancer in 2019. 

A patient with an altered FGFR2 or FGFR3 gene may benefit from this medicine. It is estimated that FGFR gene mutations are responsible for 20% of bladder cancer cases. 

Patients with advanced bladder cancer and mutations in the FGFR gene are undergoing a phase 3 trial that compares erdafitinib with standard chemotherapy and pembrolizumab. 

The purpose of this study is to determine whether erdafitinib or an immune checkpoint inhibitor may be more beneficial in treating FGFR-mutant bladder cancer patients than chemotherapy.

In phase 3 trials, patients with muscle-invasive bladder cancer are receiving chemotherapy and radiation therapy with and without immune checkpoint inhibitor atezolizumab. Radiation therapy and chemotherapy combine to kill more cancer cells than chemotherapy alone. Patients with muscle-invasive bladder cancer may achieve better outcomes when atezolizumab (Tecentriq) is combined with radiation therapy and chemotherapy. 

The monoclonal antibodies are proteins made in the laboratory and can bind to specific targets in the body, such as cancer cells. Monoclonal antibodies are chemically linked to drugs to form antibody-drug conjugates. It can kill cancer cells without harming normal cells. 

Enfortumab vedotin-ejfv (Padcev) is also approved for treating advanced or metastatic bladder cancer. Positive results have been observed in patients who have previously been treated with chemotherapy and immune checkpoint inhibitors. A study is ongoing to determine whether this drug can be used together with immunotherapy and/or chemotherapy to treat bladder cancer early.

Competitive Landscape

The report gives an in-depth analysis of the top players involved in the global bladder cancer treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows: 

• AstraZeneca Plc.

• Bristol-Myers Squibb Co.

• Celgene Corporation

• Pfizer Inc.

• GlaxoSmithKline Plc.

• Eli Lilly and Company

• F. Hoffmann-La Roche AG

• Novartis International AG

• Sanofi S.A.

• Merck & Co. Inc.

• Genetech Inc.

• Johnson & Johnson Services, Inc

• Viventia Bio Inc.

• Spectrum Pharmaceuticals, Inc.

• Herantis Pharma Plc.

• Taris Biomedical LLC

• Prometic Life Sciences Inc.

Key Highlights of the Report

Bladder Cancer Treatment Market Report Snapshots

Bladder Cancer Treatment Market Size

Bladder Cancer Treatment Market Growth

Bladder Cancer Treatment Companies